First In Ventures
VC Fund
Middletown, United States
First In Ventures is a venture capital firm that invests in biotech companies.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 26%
Last updated:
For AI agents: llms.txt
Industries First In Ventures invests in
Stages First In Ventures invests in
Countries First In Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 8 (42%)
- Health Care 6 (32%)
- Medical 3 (16%)
- Network Security 3 (16%)
- Information Technology 3 (16%)
Stage
- Seed 10 (53%)
- Pre-Seed 3 (16%)
- Series A 3 (16%)
- Series B 1 (5%)
- Series C 1 (5%)
Country
- United States 11 (58%)
- India 2 (11%)
- United Kingdom 2 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kyle Rusconi
Founder & General Partner
|
Founder & General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Antithesis develops QA software that revolutionizes the way software testing is performed. At Antithesis, the company wants to bring the confidence and productivity benefits of autonomous testing to your team. It has developed a platform that searches for bugs in your software, in a controlled environment where all bugs are reproducible. Its firstoffering finds fault tolerance bugs: failures of the software that occur under specific network, hardware, or timing conditions. | $105M / Series A / Dec 03, 2025 | ||
| Readyly is an agentic AI platform that helps governments and regulated organizations automate citizen and customer service across digital and voice channels. The platform deploys AI agents that can answer questions, guide users through complex processes, and execute workflows such as case intake, status updates, and service requests.Readylyintegrates with existing government and enterprise systems, including CRM, permitting, records, and communications platforms, allowing organizations to modernize service delivery without replacing their underlying infrastructure. The platform supports multilingual and accessible interactions, enabling governments and organizations to serve diverse populations at scale.Readyly is used by public sector organizations and regulated enterprises in the United States, Canada, the United Kingdom, and Europe, and is designed to meet the security, compliance, and reliability requirements of government environments. | $1.6M / Pre-Seed / Jan 01, 2025 | ||
| ZeroTier, Inc. offers the fastest, most flexible solution to deploy and maintain secure peer-to-peer networks. Supporting over two million devices globally with a proud open-source heritage, ZeroTier provides unrivaled ease of connectivity and management for modern networking use cases. ZeroTier is trusted by organizations in an expansive range ofglobal industries including Information Technology, Cloud, Telecommunications, IoT, Manufacturing, Media, Automotive, Aerospace, and Defense. For more information, visit https://www.ZeroTier.com or follow us on Twitter @ZeroTier. | $13.5M / Series A / Jul 26, 2024 | ||
| Antithesis develops QA software that revolutionizes the way software testing is performed. At Antithesis, the company wants to bring the confidence and productivity benefits of autonomous testing to your team. It has developed a platform that searches for bugs in your software, in a controlled environment where all bugs are reproducible. Its firstoffering finds fault tolerance bugs: failures of the software that occur under specific network, hardware, or timing conditions. | $47M / Seed / Feb 13, 2024 | ||
| The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent). | $16.5M / Series A / May 24, 2023 | ||
| Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction. | $3.2M / Seed / Jul 27, 2022 | ||
| Yali Biosciences is a food tech company that uses synthetic biology and genomics tools to make climate-smart, sustainable foods. | $3.9M / Seed / Feb 22, 2022 | ||
| AarogyaAI is an artificial intelligence-based software as a service that diagnoses drug-resistant tuberculosis. AarogyaAI uses a DNA sequence from the patient which is uploaded to SaaS. Its machine-learning algorithm then gives an output report of a comprehensive drug susceptibility status of the patient. | $700K / Seed / Jan 07, 2022 | ||
| Adlumin empowers modern organizations with advanced technology and top talent for cybersecurity and efficient IT operations. Adlumin was founded with the mission of addressing this challenge through the provision of a platform that proactively identifies the most recent vulnerabilities being exploited and swiftly responds to them in real-time.With the backing of an exceptional team of experts, Adlumin serves as a dedicated partner throughout the entire process, guiding users every step of the way. | $25M / Series B / Dec 07, 2021 | ||
| MEDiC is focusing on cancer drug targets in 3D tumor models using its proprietary CRISPR functional genomics platform. The biotech company is based in the San Francisco Bay Area. | Seed / Dec 04, 2021 | ||
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does First In Ventures invest in?
First In Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact First In Ventures?
Public channels for First In Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at First In Ventures?
The team at First In Ventures includes Kyle Rusconi (Founder & General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
